{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fio-biomarkers-qa-session-JgkEgfe_","width":444,"version":"1.0","type":"rich","title":"Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/ad097b67-7c2c-4fca-ad57-9fe16eb7e695/cliniciansxchange-podcast-io-biomarkers.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/63d4a260-a402-4c71-877b-64f74ce6e771\" height=\"200\" width=\"100%\" title=\"Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to John L. Marshall, MD; Jamie E. Chaft, MD; and Scot Niglio, MD, answer audience questions from a live CCO Webinar on biomarker testing and the impact on immunotherapy treatment for diverse solid tumors including the latest on PD-L1, dMMR/MSI-high, tumor mutation burden, and other emerging biomarkers."}